

### AZD-1222/etanercept/ixekizumab

S

#### Fever, myalgia and no therapeutic response: 2 case reports

In a case report, two men were described, of whom, a 48-year-old man exhibited no therapeutic response while being treated with etanercept and ixekizumab for psoriasis (PsO) and psoriatic arthritis (PsA), and a 76-year-old man developed fever and myalgia following vaccination with AZD-1222 [*dosages and routes not stated*].

Patient-1: A 48-year-old man, who had PsO and PsA, was treated with etanercept and ixekizumab; however, no therapeutic response was observed. Hence, he was started with the apremilast and he had stable remission of his disease for 8 months. Further, he was infected with COVID-19 along with flare of PsO and PsA. Flare of PsO and PsA resolved spontaneously after COVID-19 recovery. Then, he received COVID-19 vaccination with tozinameran.

Patient-2: A 76-year-old man, who had PsO, had been receiving apremilast from 2017. He then received first dose of COVID-19 vaccination with AZD-1222 and developed fever (38.5°C) and myalgia for 3 days [*durations of treatment to reaction onsets not stated*]. Second dose of AZD-1222 did not result in any adverse effects.

Pacifico A, et al. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast. *Clinical and Experimental Dermatology* 46: 1344-1346, No. 7, Oct 2021. Available from: URL: <http://doi.org/10.1111/ced.14723>

803618097